UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, ~~D.C.~~DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) ~~of the Securities Exchange Act of 1934~~

~~Date~~ of ~~Report~~the ~~(Date~~Securities ofExchange ~~earliest~~Act ~~event~~of ~~reported): March 5, 2024~~1934

~~LUCY~~Date ~~SCIENTIFIC~~of ~~DISCOVERY,~~Report ~~INC.~~ (~~Exact~~Date ~~name~~ of ~~registrant~~earliest asevent ~~specified~~reported): April in17, ~~its charter)~~2024

British Columbia, Canada		001-41616		98-1776120
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Lucy Scientific Discovery Inc.

~~301-1321~~(Exact ~~Blanshard~~name ~~Street~~of registrant as specified in its charter)

Victoria, British Columbia, Canada V8W 086

British Columbia, Canada		001-41616		Not Applicable
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

(Address of principal executive offices) (Zip Code)

301-1321 Blanshard Street Victoria, British Columbia, Canada		V8W 0B6
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (778) 410-5195

Not Applicable

(Former name or former address, if changed since ~~last~~ last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading ~~symbol~~Symbol(s) Name of each exchange on which registered Common Shares, no par value LSDI ~~NASDAQ~~The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (~~17 CFR~~ §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (~~17 CFR~~ §240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 15.02. ~~Termination~~Departure of aDirectors ~~Material~~or ~~Definitive~~Certain ~~Agreement~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

AsOn ~~previously~~April ~~disclosed~~17, ~~on September 12~~2024, ~~2023,~~Scott ~~Lucy Scientific Discovery~~Reeves, ~~Inc.~~ a ~~corporation~~member ~~existing~~of ~~under~~ the ~~laws~~Board of ~~the~~Directors ~~Province~~ of ~~British Columbia (“~~Lucy Scientific~~” or~~ ~~“Acquiror”),~~Discovery ~~1438430 B~~Inc.C. ~~Ltd., a corporation existing under~~ (the ~~laws of the Province of British Columbia (~~“~~SubCo~~Company”) ~~and~~, ~~Bluesky~~resigned, ~~Biologicals~~effective ~~Inc~~immediately., aMr. ~~corporation~~Reeves ~~existing~~did ~~under~~not ~~the~~resign ~~laws~~as ofa ~~the~~result ~~Province~~ of ~~British~~any ~~Columbia (“Bluesky”~~disagreement orwith ~~“Acquiree”), entered into that certain Amalgamation Agreement (~~the ~~“Agreement”)~~Company, ~~pursuant~~known to ~~which~~ ~~Acquiree~~an ~~and~~executive ~~SubCo~~officer ~~agreed~~of tothe ~~form a new amalgamated company (“Amalco”) and~~Company, ~~pursuant~~on toany amatter ~~three-cornered~~relating ~~amalgamation, Lucy Scientific was~~ to ~~issue certain of its securities to~~ the ~~securityholders~~Company’s ofoperations, ~~Acquiree~~policies ~~in exchange for common shares of the Amalco~~or practices.

~~On March 5, 2024, Lucy Scientific terminated the Agreement pursuant to Article 6.~~1 ~~of the Agreement. Lucy Scientific terminated the Agreement on the basis of the failure of Bluesky to timely provide audited financial statements.~~

In accordance with Article 7.1 of the Agreement, if any of the conditions contained in Article 6 were not fulfilled or performed by December 31, 2023, either party was able to terminate the Agreement by notice in writing to the other party.SIGNATURES

1Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SIGNATURES

	Lucy Scientific Discovery, Inc.

Date: April 22, 2024	By:	/s/ Richard Nanula
	Name:	Richard Nanula
	Title:	Chief Executive Officer

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~2

Date: March 12, 2024

Lucy Scientific Discovery, Inc. /s/ Richard Nanula Richard Nanula Chief Executive Officer & Executive Chairman

Filing Compare · Lucy Scientific Discovery, Inc.